StockWatch
·
AJANTA PHARMA · Q2 FY-2027 · PREVIEW

Q2 FY27: Can Ajanta Hold Momentum as Seasons Shift?

After Q1's 25% revenue surge and 31% PAT jump, the Street expects high-teens growth to persist. Watch whether margins defend and if US generic headwinds flex.

Q2 FY27 resultsAJANTPHARMAJANTA PHARMA LTD.24 Oct 2026 · 3 min read

What to Expect

Revenue (consolidated)

~₹1,600–₹1,700 Cr

On-plan for high-teens growth trajectory; Q1 was ₹1,626 Cr (+25% YoY)

Net Profit (PAT)

~₹320–₹360 Cr

Implies 20–21% net margin; Q1 was ₹334 Cr (+31% YoY); watch for seasonal margin deflation

Gross Margin

~78% ±100 bps

Management guided ~78% for FY27; Q1 achieved 80% (strong). Seasonal pressure possible.

EBITDA Margin

~27% ±100 bps

Q1: 28% (within guidance). Watch for opex leverage and mix shift.

A strong Q2 means revenue reaching ₹1,650+ Cr (staying above ₹1,600 threshold), PAT crossing ₹350 Cr, and both gross and EBITDA margins holding within guidance bands. A weaker-than-expected Q2 would show revenue plateauing vs Q1 or sub-₹1,600 Cr, net margin collapsing below 19%, or EBITDA margin slipping below 26%—signals of mix headwinds, US generic pressure, or cost inflation.

Tracking the Full-Year Plan

Management has guided high-teens revenue growth for FY2027—analyst consensus pegs FY27 at ₹6,270 Cr (+14.9% YoY). Q1's 25% growth is ahead of the full-year plan, but Q2 typically sees seasonal headwinds in pharma (monsoon, festival demand patterns). On-track means Q2 sustains 15–20% YoY growth. If sequential revenue softens sharply (say, below ₹1,550 Cr), it would signal either gross-margin compression or volume deceleration—red flags for full-year guidance.

What the Street Says

Since Last Quarter: Filings Scan

Key events (Oct 2026 lookback)

Oct 21, 2026

30,000 shares pledged (Oct 16) for 'top-up call' on existing loan. Routine refinancing.

Promoter Pledge: Aayush Agrawal

Oct 15, 2026

Oct 30 agenda: approve Q2 FY27 results. Standard governance.

Board Meeting Announced

Oct 6, 2026

Aayush Agrawal pledged 4.6L shares to back Non-Convertible Debenture (NCD) issuance. Capital raise.

Promoter NCD Pledge

Oct 1, 2026

2.10% of capital (26.21L shares) pledged as security for debt. Standard practice for leverage.

CTL Trusteeship Pledge

Sep 30, 2026

Filed GRI-referenced ESG disclosure. Voluntary, no material impact.

FY26 Sustainability Report

Sep 25, 2026

Closure per SEBI Insider Trading Regulations for Q2 result announcement. Routine.

Trading Window Closed

Pledges: Promoter leverage is rising—Aayush Agrawal and CTL Trusteeship have created multiple pledges since August (NCDs, refinance calls). This reflects debt-funded capex (likely for the liquid-formulations plant expansion). Not a red flag yet, but watch pledge-to-holding ratio if it creeps above 30–35% of promoter stake. ESG filing: Routine GRI disclosure, no operational surprise. Investor outreach: Management attended Jefferies and PL Capital conferences in August–September—confidence-building before result.

What to Watch on Oct 30

Result Day Checklist
  • 1 · Revenue & Volume Growth

    Did Q2 sustain ₹1,600+ Cr? Look for YoY growth rate (targeting 15–20% for on-plan) and segment breakdown (India domestic vs. US generics). Sequential dip is normal but magnitude matters.

  • 2 · Margin Defense

    Gross margin at ~78% and EBITDA at ~27% = on-track. Falls below 26.5% EBITDA or 77% gross? Flag cost/mix pressure. Q1's 28% EBITDA was strong—seasonal softening to 26–27% is expected.

  • 3 · FY27 Guidance Reaffirm

    Management to comment on full-year high-teens growth, margin bands, and any US generic outlook shifts. Quiet = confidence. Guidance cut = sector headwind.

  • 4 · Capital & Dividend

    FY26 saw ₹32/share interim dividend in Q1. Watch for Q2 distribution and any capex spend update on the liquid-plant project (funded via NCD pledges).

Ajanta enters Q2 with significant momentum—Q1's 25% revenue and 31% profit growth has set a high bar, and the 86.7% Buy consensus reflects confidence in FY27's high-teens growth plan. The Street's 2.2% upside from here is modest, signaling the stock is fairly valued on delivery risk.

The real test: can Q2 sustain ₹1,600+ Cr revenue while defending margins as seasonal headwinds emerge? Gross margin holds at ~78%, EBITDA at ~27%, and management reaffirms full-year guidance—those are the three pillars that keep the upside intact. A beat on volume or surprise capex efficiency could ignite a re-rating.

Informational and educational content only. Not investment advice.